Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

NCT00034892 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00034892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2002
Completion date
March 31, 2005
Enrollment
Not reported
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

mental disorders, mental health, psychotic disorders, schizophrenia